[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lipidomics\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lipidomics":32},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,67,110,142,174],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":33,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":66},"100610251","goat-milk-derived-formula-vs-undiluted-goat-milk-in-infants-unable-to-exclusively-breastfeed-growth-and-biomarker-analysis-100610251",false,"NCT07225153","Goat Milk-Derived Formula vs. Undiluted Goat Milk in Infants Unable to Exclusively Breastfeed: Growth and Biomarker Analysis","Goat Milk-Derived Formula Alternatives vs. Undiluted Goat Milk in Babies Unable to Exclusively Breastfeed: Analysis of Growth Metrics and Biological Markers","GMDFA","Inclusion Criteria:\n\n* • Infants aged = 08 -10 weeks with WAZ better than -1.8. (NIPS \\& ICF, 2019) Age Sex WAZ Weight in Kilograms 2 Month Boys WAZ\\>-1.8 4-5 kg 2 Month Girls WAZ\\>-1.8 4-5 kg Table 3: WAZ scores\n\n  * Living in Matiari District.\n  * Who has access to goat milk in their households.\n  * The Breastfeeding group: Women who exclusively breastfeeding and not giving and sort of formula or animal derived milk.\n  * Intervention Group: Women who do not breastfeed at all or give goat milk to their infants (2-3 feeds per day).\n  * No birth deformities\n\nExclusion Criteria:\n\n* • Infant birth weight \\\u003C WAZ -1.8 i.e. weight-for-age based on established growth standards, such as the World Health Organization (WHO).\n\n  * Birth deformities or disorders, such as genetic disorders, aerodigestive problems, or congenital anomalies.\n  * Plan to migrate during the next six months.\n  * We will exclude the women who exclusive breast feed and continue breast feeding for first 4 months.\n  * If the child is enrolled or included in any other interventional trial.\n  * Who does not have access to goat milk in their households.\n  * Are medically disqualified: Any potential participant who is deemed medically unfit for enrollment, due to the presence of severe or unstable health conditions that could compromise safety or interfere with the study outcomes, will be excluded from participation","ALL","8 Weeks","10 Weeks",{"count":21,"type":22},15,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this clinical trial is to learn if Goat Milk-Derived Formula Alternatives (GMDFA) are safe and effective for infants who are unable to be exclusively breastfed. It will also study growth patterns, biological markers, and gut microbiome differences among infants receiving GMDFA, undiluted goat milk, or breast milk.\n\nThe main questions it aims to answer are:\n\n1. Do infants receiving GMDFA show similar growth patterns to those who are breastfed?\n2. Are biological markers of gut health and nutrition (such as calprotectin, lipocalin-2, CRP, and claudin) comparable between the groups?\n3. How do feeding types (GMDFA, goat milk, or breast milk) influence the infant gut microbiome composition, metabolic pathways, and lipid profiles?\n4. Is GMDFA a safe and nutritionally adequate feeding option for infants unable to be exclusively breastfed?\n\nWe will compare GMDFA, undiluted goat milk, and breast milk (reference group) to evaluate infant growth, gut health, and metabolic outcomes.\n\nParticipants will:\n\nBe randomly assigned to one of three feeding groups: GMDFA, undiluted goat milk, or breastfed\n\nAttend regular follow-up visits for growth measurements and sample collection (blood, stool, and breast milk where applicable)\n\nHave feeding practices monitored and recorded through caregiver interviews and feeding logs\n\nAdditional Analyses:\n\nMicrobiome analysis: to identify gut bacterial diversity and composition across feeding groups Metagenomic analysis: to explore functional genes and metabolic pathways related to nutrition and gut health Lipidomic analysis: to assess differences in lipid and fatty acid profiles in breast milk, goat milk, and infant samples",[28,29,30,31,32],"Malnutrition (Calorie)","Infant Nutrition Disorder","Growth Flatering","Gut Microbiome","Lipidomics",[34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,32,52,53],"Infant nutrition","goat milk","Infant feeding practices","Breastfeeding","Breastfeeding Alternatives","Alternate feeding practices","Growth outcomes","Infant growth metrics","Gut microbiome","Gut inflammation biomarkers","Calprotectin","Lipocalin-2","Claudin-2","C-reactive protein (CRP)","Randomized controlled trial","Rural Pakistan","Infant health","Malnutrition prevention","Breast milk","Metagenomics","RECRUITING","2026-03-25",{"date":57,"type":58},"2026-03-30","ACTUAL",{"date":60,"type":58},"2025-08-30",{"date":62,"type":22},"2026-03-18",{"name":64,"class":65},"Aga Khan University","OTHER",1,{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":17,"minAge":75,"maxAge":4,"enrollmentInfo":76,"targetDuration":4,"studyType":23,"phases":78,"briefSummary":80,"conditions":81,"keywords":90,"overallStatus":100,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":66},"100585948","phase-3-semaglutide-treatment-in-type-1-diabetes-100585948","NCT06909006","Semaglutide Treatment in Type 1 Diabetes","Obesity and Semaglutide in Type 1 Diabetes Therapy: A Multicentre, Randomised, Double-Blinded, Placebo-Controlled, Investigator-Initiated Trial","OBES1TY","Inclusion Criteria:\n\n* Type 1 Diabetes for more than 3 years\n* BMI ≥ 30 or ≥ 27 and atleast one comorbidity (hypertension, hypercholesterolemia, microalbuminuria, ischemic heart disease, history of stroke, atherosclerosis or arthrosis\n\nExclusion Criteria:\n\n* Treated with GLP1-RAs within last 6 months\n* Known intolerance for semaglutide\n* Other forms of diabetes\n* Pregnant or nursing women\n* Fertile women not using chemical (hormonal) or mechanical (spiral) contraceptives\n* Liver disease with elevated plasma alanine aminotransferase (ALT) \\> five times and plasma aspartate aminotransferase (AST) \\> five times the upper limit of normal (measured at visit 0 with the possibility of one repeat analysis within a week, and the last measured value as being conclusive)\n* Acute or chronic pancreatitis\n* Cancer, unless in complete remission for \\> 5 years or unless basocellular carcinomas\n* History of thyroid adenoma or carcinoma\n* Alcohol\u002Fdrug abuse\n* Other concomitant disease or treatment that according to the investigator's assessment makes the patient unsuitable for study participation\n* Receipt of an investigational drug within 30 days prior to visit 0 \u002F Simultaneous participation in any other clinical intervention trial","18 Years",{"count":77,"type":22},122,[79],"PHASE3","The goal of this clinical trial is to investigate the efficacy of semaglutide on body weight, insulin dose requirements and improvements in glucose control and safety aspects in regards to risk of hypoglycemia and diabetic ketoacidosis for patients with established Type 1 Diabetes.",[82,83,84,85,86,32,87,88,89],"Obesity in Diabetes","Obesity\u002FTherapy","Type 1 Diabetes Mellitus (T1DM)","Insulin Sensitivity\u002FResistance","Semaglutide","Metabolomics","Weight Loss","Glycemic Control for Diabetes Mellitus",[86,91,92,93,94,95,96,97,98,99],"Obesity","Type 1 Diabetes","Obese Type 1 Diabetics","Insulin sensitivity","Insulin resistance","Weight loss","GLP1-RA","GLP1","Wegovy","NOT_YET_RECRUITING","2025-08-04",{"date":103,"type":58},"2025-08-08",{"date":105,"type":22},"2025-10",{"date":107,"type":22},"2028-06",{"name":109,"class":65},"Nordsjaellands Hospital",{"id":111,"slug":112,"hasResults":11,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":4,"eligibilityCriteria":116,"healthyVolunteers":11,"sex":17,"minAge":75,"maxAge":117,"enrollmentInfo":118,"targetDuration":4,"studyType":120,"phases":4,"briefSummary":121,"conditions":122,"keywords":127,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":66},"100426368","bio-significance-of-lpc160-in-fibromyalgia-100426368","NCT04832100","Bio-significance of LPC16:0 in Fibromyalgia","A Clinical Approach to Validate the Biological Significance of LPC16:0 as a Discriminating and Pathogenic Biomarker of Fibromyalgia","Inclusion Criteria:\n\n1\\. Clinical diagnosis of fibromyalgia\n\nExclusion Criteria:\n\n1. Systemic rheumatological or immune disorders (e.g., systemic lupus erythematosus, inflammatory myositis),\n2. Systemic use of corticosteroids,\n3. Pregnancy,\n4. Chronic diseases under poor control\n5. Malignancies.","70 Years",{"count":119,"type":22},245,"OBSERVATIONAL","Fibromyalgia (FM) is a very common but mysterious pain disorder characterized by chronic widespread muscular pain. Fatigue, anxiety and depression are common comorbidities. The syndrome is commonly associated with several symptoms, including fatigue, sleeping disturbance, cognitive impairment, and comorbid pain syndrome, especially irritable bowel symptoms and temporomandibular disease. Anxiety and depression are common psychiatric co-morbidies. Daily stress is believed to trigger or aggravate pain conditions. These symptoms can markedly affect patients' quality of life, and even lead to disability. So far, the etiology and pathogenesis are largely unknown, and diagnostic biomarkers and curative treatment remain to be developed. Recent technological advances enable scientists to explore mechanisms by genetic, transcriptomic, proteomic, and metabolomic researches. However, no definitive result has been concluded for clinical practice so far.\n\nIn this study, the investigators use tailored questionnaires to evaluate fibromyalgia and associated symptoms, including numeric rating scale for soreness, widespread soreness index, Fibromyalgia impact questionnaire, Hospital Anxiety and Depression Scale, and perceived stress scale. The investigators also use metabolomics and lipidomic approach to probe the potential pathophysiology of fibromyalgia. In our prior translation research (PMID: 32907805), the investigators found that excessive LPC16:0 resulting from lipid oxidization inflicts psychological stress-induced chronic non-inflammatory pain via activating ASIC3. In this content, our prior translational research identified a potential nociceptive ligand that causes fibromyalgia symptoms, which is likely to function as biomarkers for diagnosis or disease monitor. In the current clinical investigation, the investigators aim to reversely translate the novel findings in animal studies and validate the bio-significance of LPC16:0 for fibromyalgia with clinical approaches.",[123,124,125,126,87,32],"Fibromyalgia, Primary","Pain","Soreness, Muscle","Oxidative Stress",[128,129,130,131,132],"lysophosphotidylcholine","fibromyalgia","pain","soreness","metabolomics","2025-06-22",{"date":135,"type":58},"2025-06-26",{"date":137,"type":58},"2021-06-01",{"date":139,"type":22},"2027-06-30",{"name":141,"class":65},"Kaohsiung Medical University Chung-Ho Memorial Hospital",{"id":143,"slug":144,"hasResults":11,"nctId":145,"briefTitle":146,"officialTitle":147,"acronym":4,"eligibilityCriteria":148,"healthyVolunteers":11,"sex":17,"minAge":75,"maxAge":149,"enrollmentInfo":150,"targetDuration":152,"studyType":120,"phases":4,"briefSummary":153,"conditions":154,"keywords":159,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":172,"locationsCount":66},"100586439","metabolomic-and-lipidomic-analysis-predicts-immunotherapy-related-adverse-events-in-gastric-cancer-patients-100586439","NCT06915389","Metabolomic and Lipidomic Analysis Predicts Immunotherapy-related Adverse Events in Gastric Cancer Patients","Comprehensive Plasma Metabolomic and Lipidomic Profiling for Predictive Modeling and Biomarker Discovery of Immune-Related Adverse Events in PD-1\u002FPD-L1 Inhibitor-Treated Gastric Cancer Patients: A Prospective Cohort Study","Inclusion Criteria:\n\n* Age≥ 18 years\n\n  * ECOG PS 0-2\n\n    * Gastric cancer diagnosed by histology or cytology\n\n      * Untreatment with PD-1\u002FPD-L1 inhibitors\n\n        * Expected survival≥3 months\n\n          * Exhibits a favorable adherence to treatment and follow-up,demonstrates compliance with the research protocol, and willingly signs the informed consent form.\n\nExclusion Criteria:\n\n* Unable to obtain an organization or due to insufficient organizational material, unable to diagnose gastric cancer\n\n  * Refusal to receive PD-1\u002FPD-L1 inhibitor treatment\n\n    * Baseline (before immunotherapy) plasma samples are unavailable\n\n      * Combined with autoimmune diseases\n\n        * Baseline (before immunotherapy) there are severe diseases in the heart, lungs, thyroid gland and other organs\n\n          * Baseline (before immunotherapy) there are severe abnormalities in liver and kidney functions, pancreatic enzymes and other indicators\n\n            ⑦ Researchers posit that any condition deemed potentially harmful to the subjects or that might prevent subjects from meeting or adhering to the research requirements shall not be permissible for inclusion in this study","80 Years",{"count":151,"type":22},100,"1 Year","This study comprehensively examines metabolic and lipidomic dynamics in gastric cancer patients initiating PD-1\u002FPD-L1 inhibitor therapy, employing a longitudinal design with pre- and post-treatment patients. The primary objectives include identifying irAE-associated metabolic and lipid biomarkers, developing predictive risk models, and evaluating the prognostic value of these molecular profiles. The findings are expected to contribute significantly to personalized treatment strategies and improved clinical decision-making in immunooncology.",[155,156,157,158,32],"Gastric Cancer","Immunotherapy","Adverse Event","Metabonomics",[160,161,162,163,164,165],"Immune-related adverse events (irAEs)","PD-1\u002FPD-L1 inhibitors","Gastric cancer","Biomarkers","Metabolic","Lipidomic","2025-04-03",{"date":168,"type":58},"2025-04-08",{"date":170,"type":58},"2025-02-22",{"date":139,"type":22},{"name":173,"class":65},"Qinghai Red Cross Hospital",{"id":175,"slug":176,"hasResults":11,"nctId":177,"briefTitle":178,"officialTitle":179,"acronym":180,"eligibilityCriteria":181,"healthyVolunteers":182,"sex":17,"minAge":75,"maxAge":183,"enrollmentInfo":184,"targetDuration":4,"studyType":23,"phases":186,"briefSummary":187,"conditions":188,"keywords":4,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":206,"lastUpdatePostDateStruct":207,"startDateStruct":209,"completionDateStruct":211,"leadSponsor":213,"locationsCount":66},"100462875","cancer-associated-muscle-mass---molecular-factors-and-exercise-mechanisms-100462875","NCT05307367","Cancer-associated Muscle Mass - Molecular Factors and Exercise Mechanisms","Identifying Molecular Factors Contributing to Cancer-associated Muscle Mass Loss and Providing Clinical Evidence for Exercise Mechanisms to Functionally Restore Muscle in Cancer","PANACEA","Inclusion Criteria, WP1+WP2X+WP2:\n\n* Men and women at or above the age of 18\n* Histological and radiological verified NSCLC (both squamous and adenocarcinoma) st. IIIb\u002FIV stage not eligible to concurrent chemo\u002Fradiation therapy as primary treatment\n* Referred for 1st line palliative anticancer therapy (platin based, immunotherapy, combined therapy or TKI), this goes for WP1 + WP2\n* Referred for palliative anticancer therapy (platin based, immunotherapy, combined therapy or TKI), for recurrent cancer, this goes only for WP2X.\n* Having a staging\u002Fbaseline CT within 4 weeks of initiation of treatment (PET\u002FCT are also allowed), or a baseline scan planned within the first week of treatment.\n* ECOG Performance Status 0-2\n* Having signed the informed consent form\n\nExclusion Criteria, WP1+WP2X+WP2:\n\n* Any other known malignancy requiring active treatment (prior cancer diagnosis is not some exclusion criteria if oncology-treatment is completed)\n* Local palliative radiotherapy as primary treatment\n* ECOG Performance status \\> 2\n* Physical disabilities excluding physical testing\n* Inability to understand Danish\n* Inability to understand scoring systems\u002Fpatient-reported outcome measures\n\nInclusion Criteria, WP3:\n\n* Men and women above the age of 18\n* Histological and radiological verified NSCLC (both squamous and adenocarcinoma) st. IIIb\u002FIV stage\n* ECOG Performance Status 0-2\n* Having signed the informed consent form.\n\nExclusion Criteria, WP3:\n\n* Any other known malignancy requiring active treatment (prior cancer diagnosis is not some exclusion criteria if oncology-treatment is completed)\n* ECOG Performance Status \\> 2\n* Physical disabilities excluding physical testing\n* Inability to understand Danish\n* Inability to understand scoring systems\u002Fpatient-reported outcome measures",true,"100 Years",{"count":185,"type":22},144,[25],"Muscle mass loss is a common adverse effect of cancer. Muscle mass loss occurs with or without reduction in body weight. Cancer cachexia (CC) is the involuntary loss of body weight of \\>5% within 6 months and it occurs in 50-80% of patients with metastatic cancer.\n\nIt is estimated that CC is a direct cause of up to 30% of all cancer-related deaths. No treatment currently is available to prevent CC, likely because the chemical reactions that causes of this devastating phenomenon in unknown.\n\nNo treatment currently is available to prevent muscle mass loss in patients with cancer but is urgently needed as the reduced muscle mass and function is associated with impaired physical function, reduced tolerance to anticancer therapy, poor quality of life (QoL), and reduced survival. There is evidence of an interdependence between informal caregiver (e.g. spouse) and patient QoL. Thus, identifying caregiver distress and needs can potentially benefit QoL for patients with cancer cachexia. Despite the enormous impact on disease outcomes, it is not known why the loss of muscle mass and function occurs and very few studies have investigated the underlying molecular causes in humans. In particular, there is a severe lack of studies that have obtained human skeletal muscle and adipose tissue sample material. Such reference sample materials will be invaluable to obtaining in-depth molecular information about the underlying molecular causes of the involuntary but common muscle mass and fat mass loss in cancer.\n\nAt a whole body level, cancer cachexia is associated with reduced sensitivity to the hormone insulin, high levels of lipids in the blood, and inflammation. Within the skeletal muscle, the muscle mass loss is associated with elevated protein breakdown and reduced protein build-up while emerging, yet, limited data also suggest malfunction of the power plants of the cells called mitochondrions. The role of malnutrition and how it contributes to weight loss is understood only to the extent of the observed loss of appetite and the reduced food intake because of pain, nausea, candidiasis of the mouth, and breathlessness. Evidence is increasing that the environment of the intestinal system could be implicated in cancer cachexia, yet, the possible effect of cancer and the cancer treatment on the intestinal environment is not understood. Thus, large and as yet poorly understood details of this syndrome precede a later weight loss.\n\nExercise training could help restore muscle function and how the chemical reactions works in cancer. In healthy people, and patients with diabetes, cardiovascular disease, and obesity exercise potently improves health. Exercise has been thought to slow down the unwanted effects of cancer cachexia by changing the reactions mentioned above. Thus, there is a tremendous gap in our knowledge of how and if exercise can restore the cells power plants function, muscle mass, strength, and hormone sensitivity in human cachexic skeletal muscle. Tackling that problem and examining potential mechanisms, will enable us to harness the benefits of exercise for optimizing the treatment of patients with cancer.\n\nThe data will provide novel clinical knowledge on cachexia in cancer and therefore addressing a fundamental societal problem.\n\nThree specific aims will be addressed in corresponding work packages (WPs):\n\n* investigate the involvement of hormone sensitivity of insulin and measure the chemical reactions between the cells in patients with lung cancer (NSCLC) and describe the physical performance and measure amount of e.g. muscles and adipose tissue across the 1st type of cancer treatment and understand how that is related to the disease and how patients and informal caregiver feel (WP1).\n* find changes in the chemical reactions in skeletal muscle, adipose tissue (AT), and blood samples in these patients, to understand how to predict how the disease will develop (WP2).\n* measure changes of skeletal muscle tissue in response to exercise and see if it might reverse the hormone insensitivity and improve muscle signaling and function (WP3).\n\nThe investigators believe that:\n\n* the majority of patients with advanced lung cancer, at the time of diagnosis already are in a cachectic state, where they lose appetite, and have hormonal changes, and an overall altered chemical actions between the cells affecting both muscle mass and AT. The investigators propose that all this can predict how the disease will progress, and how patient- and informal caregiver fell and how they rate their quality of life.\n* lung cancer and the treatment thereof is linked with changes in the blood, the muscle tissues, and the adipose tissues, especially in patients experiencing cachexia, that could be targeted to develop new treatment.\n* exercise can restore the muscles and improve insulin sensitivity and improve the function of the cells power plants in patients with lung cancer-associated muscle problems.",[189,190,191,192,193,194,195,196,197,198,199,200,201,202,203,32,204,205],"Cachexia","Neoplasms","Exercise","Metabolism","Body Composition","Insulin Resistance","Physical Functional Performance","Quality of Life","Sarcopenia","Caregivers","Adipose Tissue","Muscle, Skeletal","Patient Reported Outcome Measures","Gastrointestinal Microbiome","Proteomics","Epigenomics","Mitochondria","2022-05-09",{"date":208,"type":58},"2022-05-16",{"date":210,"type":58},"2022-04-01",{"date":212,"type":22},"2028-01-01",{"name":214,"class":65},"University of Copenhagen"]